IO-108

BIOLOGICAL2 trials

Sponsors

Immune-Onc Therapeutics

Conditions

Advanced Solid TumorSolid Tumor, Adult

Phase 1

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

CompletedNCT05054348

Immune-Onc TherapeuticsSolid Tumor, Adult

Start: 2021-09-30End: 2024-05-31Updated: 2024-06-04

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

CompletedNCT05508100

Immune-Onc TherapeuticsAdvanced Solid Tumor

Start: 2022-09-09End: 2024-04-30Updated: 2024-05-24

Related Papers

Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2024-11-014 citations

Abstract CT040: A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors: Dose escalation study

Cancer Research2023-04-146 citations

Abstract CT209: A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348)

Cancer Research2022-06-154 citations

Abstract 601: IO-108, A fully human therapeutic antibody blocking the myeloid checkpoint LILRB2/ILT4, promotes innate and adaptive anti-cancer immunity in preclinical studies

Cancer Research2022-06-154 citations